Candriam Luxembourg S.C.A. lowered its position in Axovant Sciences Ltd. (NYSE:AXON) by 41.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 93,000 shares of the biotechnology company’s stock after selling 67,000 shares during the period. Candriam Luxembourg S.C.A.’s holdings in Axovant Sciences were worth $2,157,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in AXON. Bank of America Corp DE increased its stake in shares of Axovant Sciences by 38.9% in the first quarter. Bank of America Corp DE now owns 7,396 shares of the biotechnology company’s stock worth $111,000 after buying an additional 2,072 shares in the last quarter. AQR Capital Management LLC purchased a new stake in shares of Axovant Sciences during the fourth quarter worth about $139,000. Oppenheimer & Co. Inc. purchased a new stake in shares of Axovant Sciences during the first quarter worth about $219,000. American International Group Inc. increased its stake in shares of Axovant Sciences by 7.1% in the first quarter. American International Group Inc. now owns 15,052 shares of the biotechnology company’s stock worth $225,000 after buying an additional 998 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its stake in shares of Axovant Sciences by 38.5% in the second quarter. Russell Investments Group Ltd. now owns 10,041 shares of the biotechnology company’s stock worth $233,000 after buying an additional 2,789 shares in the last quarter. Institutional investors and hedge funds own 94.35% of the company’s stock.

Shares of Axovant Sciences Ltd. (NYSE AXON) opened at 21.91 on Friday. Axovant Sciences Ltd. has a 12-month low of $11.01 and a 12-month high of $26.49. The firm’s market cap is $2.36 billion. The company has a 50-day moving average of $22.97 and a 200 day moving average of $19.04.

Axovant Sciences (NYSE:AXON) last issued its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.53) by $0.12. Equities research analysts anticipate that Axovant Sciences Ltd. will post ($2.32) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Axovant Sciences Ltd. (AXON) Stake Lowered by Candriam Luxembourg S.C.A.” was first published by Watch List News and is the property of of Watch List News. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The correct version of this article can be accessed at https://www.watchlistnews.com/axovant-sciences-ltd-axon-stake-lowered-by-candriam-luxembourg-s-c-a/1472850.html.

AXON has been the subject of a number of recent analyst reports. BidaskClub upgraded shares of Axovant Sciences from a “hold” rating to a “buy” rating in a report on Friday, June 23rd. Jefferies Group LLC restated a “buy” rating and set a $31.00 price target on shares of Axovant Sciences in a report on Tuesday, April 18th. CIBC raised their price target on shares of Axovant Sciences from $30.00 to $33.00 and gave the stock a “neutral” rating in a report on Tuesday, April 18th. Oppenheimer Holdings, Inc. raised their price target on shares of Axovant Sciences from $30.00 to $33.00 and gave the stock a “neutral” rating in a report on Monday, April 17th. Finally, Cowen and Company restated an “outperform” rating and set a $30.00 price target on shares of Axovant Sciences in a report on Wednesday, June 21st. Two research analysts have rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $28.50.

Axovant Sciences Company Profile

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Want to see what other hedge funds are holding AXON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axovant Sciences Ltd. (NYSE:AXON).

Institutional Ownership by Quarter for Axovant Sciences (NYSE:AXON)

Receive News & Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.